Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brachytherapy Inconvenience Driving Off-Label DES Use – Novoste

This article was originally published in The Gray Sheet

Executive Summary

Novoste is looking to expanded indications for brachytherapy, such as treatment of arterial-venous dialysis graft occlusions, to overcome competition from vascular stenting

You may also be interested in...



Guidant Transfers Accounts To Novoste, Exits Vascular Brachytherapy

Guidant will terminate production of its Galileo intravascular radiotherapy system and exit the vascular brachytherapy (VBT) market altogether over the next six months, the firm announced April 22

Guidant Transfers Accounts To Novoste, Exits Vascular Brachytherapy

Guidant will terminate production of its Galileo intravascular radiotherapy system and exit the vascular brachytherapy (VBT) market altogether over the next six months, the firm announced April 22

Cypher Stars In “Real World” Dutch Registry Of High-Risk Patients

J&J/Cordis' SISR pivotal trial is comparing the Cypher sirolimus-eluting stent with intravascular brachytherapy for treatment of in-stent restenosis

UsernamePublicRestriction

Register

LL1134786

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel